Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pre-Clinical QT Prolongation Guidance Urges In Vitro, In Vivo Studies

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA's 1draft guidance on preclinical evaluation of QT prolongation urges drug companies to initiate follow-up studies when nonclinical studies are inconsistent

You may also be interested in...



FDA Seeks Specificity Over Sensitivity To ID Potentially Proarrhythmic Drugs

The agency is looking at preclinical measurement of a drug’s effect on multiple ion channels, in silico modeling and stem cell assays as a possible alternative to “thorough” QT tests to assess the therapy’s impact on heart rhythm.

FDA Will Accept QT/QTc Comments Through Mid-February

The agency is reopening the comment period for the International Conference on Harmonization QT prolongation draft guidances after a request from Wyeth. The comment period had ended in December.

FDA Will Accept QT/QTc Comments Through Mid-February

The agency is reopening the comment period for the International Conference on Harmonization QT prolongation draft guidances after a request from Wyeth. The comment period had ended in December.

Related Content

Topics

UsernamePublicRestriction

Register

PS060528

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel